Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) TrialMarc A. Pfeffer, Bertram Pitt, Brian Claggett et al.|Circulation|2014Cited by 1k
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival AnalysisHajime Uno, L. J. Wei, Brian Claggett et al.|Journal of Clinical Oncology|2014Cited by 777
Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysisSara B. Seidelmann, Scott D. Solomon, Brian Claggett et al.|The Lancet Public Health|2018Cited by 766
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trialsMuthiah Vaduganathan, Scott D. Solomon, Brian Claggett et al.|The Lancet|2020Cited by 645
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fractionScott D. Solomon, Marc A. Pfeffer, Brian Claggett et al.|European Heart Journal|2015Cited by 524